Omega Healthcare Investors Q2 2024 Earnings Report

Omega Healthcare Investors EPS Results

• Actual EPS: $0.45
• Consensus EPS: $0.65
• Beat/Miss: Missed by -$0.20
• One Year Ago EPS: $0.74

Omega Healthcare Investors Revenue Results

• Actual Revenue: $252.70 million
• Expected Revenue: $205.92 million
• Beat/Miss: Beat by +$46.78 million
• YoY Revenue Growth: +17.50%

Omega Healthcare Investors Announcement Details

• Quarter: Q2 2024
• Date: 8/1/2024
• Time: After Market Closes
• Conference Call Date: Friday, August 2, 2024
• Conference Call Time: 10:00AM ET

Omega Healthcare Investors (NYSE:OHI) is a real estate investment trust (REIT) that specializes in the ownership and management of healthcare-related facilities. The company’s core business involves acquiring and leasing long-term care properties, including skilled nursing facilities and assisted living communities, under net lease agreements. Its portfolio is designed to provide stable, inflation-protected cash flows from operators responsible for day-to-day property management.

Founded in 1992 and headquartered in Hunt Valley, Maryland, Omega Healthcare Investors has grown its holdings to encompass hundreds of facilities across the United States, with a smaller presence in select international markets. The company focuses on sale-leaseback transactions and portfolio acquisitions, partnering with leading healthcare providers to expand or reposition their real estate. Its portfolio diversification by geography and operator credit quality aims to mitigate market concentration risk.

Omega Healthcare Investors is led by a management team with extensive experience in real estate investment, healthcare operations, and capital markets. The board and senior leadership oversee strategic capital allocation, asset acquisitions, and lease structuring to maintain a high-quality portfolio. Through disciplined underwriting and active asset management, the company seeks to deliver long-term growth and income to its shareholders.

Omega Healthcare Investors Q2 2024 Earnings Call Transcript

Key Takeaways

• Q2 FAD of $0.68 per share exceeded expectations, dividend payout ratio fell below 100%, and 2024 AFFO guidance was narrowed and raised to a range of $2.78–$2.84 per share.
• Portfolio operating trends strengthened as operator EBITDAR coverage improved to 1.42× from 1.33× and occupancy rebounded to 80.8% as of mid-July 2024.
• LaVie’s Chapter 11 filing initiated a restructuring expected to support approximately $36 million in annual rent, with final court resolution anticipated by year-end and increased counterparty risk in the interim.
• Omega acquired the remaining 51% interest in a UK joint venture, adding 63 facilities and assuming $243 million of 10.38% secured debt, which it plans to refinance by November 2025.
• The investment pipeline remains robust, with $702 million of new investments closed year-to-date at an average yield of 10.4% and share issuances funding growth while keeping leverage under 5× EBITDA.

Presentation

[Operator]

Greetings, and welcome to the Omega Healthcare Investors Second Quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After today's presentation, there will be a brief question and answer session. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to Michele Reber. Thank you. You may begin.

[Michele Reber, Managing Director of Operations at Omega Healthcare Investors]

Thank you, and good morning. With me today is Omega's CEO, Taylor Pickett, COO, Dan Booth, CFO, Bob Stephenson, and Megan Krull, Senior Vice President of Operations. Comments made during this conference call that are not historical facts may be forward-looking statements, such as statements regarding our financial projections, potential transactions, operator prospects, and outlook generally. Factors that could cause actual results to differ materially from those in the forward-looking statements are detailed in the company's filings with the SEC. During the call today, we will refer to some non-GAAP financial measures such as NAREIT FFO, adjusted FFO, FAD, and EBITDA. Reconciliations of these non-GAAP measures to the most comparable measure under generally accepted accounting principles are available in the quarterly supplement. In addition, certain operator coverage and financial information that we discuss is based on data provided by our operators that has not been independently verified by Omega.I will now turn the call over to Taylor.

[Taylor Pickett, CEO at Omega Healthcare Investors]

Thanks, Michele. Good morning, and thank you for joining our second quarter 2024 earnings conference call. Today, I will discuss our second quarter financial results and certain key operating trends. Second quarter FAD, Funds Available for Distribution of $0.68 per share, was better than expected and should continue to improve as several portfolios are in the process of being transitioned, which will result in FAD upside over the next few quarters. Our dividend payout ratio is now below 100% and should continue to drop into the mid-90% range in the upcoming quarters. As a result of year-to-date portfolio transitions and acquisitions, we have narrowed and increased our 2024 AFFO guidance to a range of $2.78 per share-$2.84 per share.

[Taylor Pickett, CEO at Omega Healthcare Investors]

We have issued a significant amount of equity to fund our robust pipeline, which has helped to further delever the balance sheet. As Dan will discuss, key tenant occupancy and rent coverage metrics continue to improve. The under one times EBITDA coverage operator metric dropped to 8.9% of total rent. In looking at the 8.9% balance of below one times operators, we can break the 8.9% into two buckets. Operators representing 6.1% of the 8.9% are strong credits and therefore payment of rent should not be an issue. That leaves operators representing 2.8%, consisting of 8 small relationships. On July 24th, we, as the 49% minority partner in a real estate joint venture, closed on the acquisition of the remaining 51% joint venture interest.

[Taylor Pickett, CEO at Omega Healthcare Investors]

We now own a 100% interest in the 63 U.K. facilities previously owned by the joint venture. The acquisition included the assumption of $243 million in secured debt. It is our intention to repay the secured debt in November 2025, as prepayment of the debt prior to November 2025 will result in significant prepayment penalties. The interest rate of 10.38% on the assumed debt is significantly above Omega debt market rates. For GAAP accounting purposes, the above-market portion of the interest expense is capitalized as part of the joint venture acquisition. We intend to use this same GAAP accounting treatment for our FFO, adjusted FFO, and FAD calculations. Lastly, after more than four years of COVID-related industry issues, the industry has generally recovered to pre-COVID operating metrics. The combination of strong demographics and limited or no new supply should bode well for our operating partners. I will now turn the call over to Bob.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Thanks, Taylor, and good morning. Turning to our financials for the second quarter. Revenue for the second quarter was $253 million compared to $250 million for the second quarter of 2023. The year-over-year increase is primarily the result of the timing and impact of operator restructurings, transitions, and revenue from new investments completed throughout 2023 and 2024, partially offset by asset sales completed during that same time period. Our NAREIT FFO for the second quarter was $189 million, or $0.72 per share, as compared to $155 million or $0.63 per share for the second quarter of 2023.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our adjusted FFO was $185 million or $0.71 per share for the quarter, and our FAD was $177 million or $0.68 per share, and both exclude several items outlined in our NAREIT FFO, adjusted FFO, and FAD reconciliations to net income found in our earnings release, as well as our second quarter financial supplemental posted to our website. Our second quarter FAD was $0.023 greater than our first quarter FAD. As outlined in our press release, the Guardian portfolio did not pay in Q1 and was transitioned to a new operator in April with an annual base rent of $5.5 million, an additional annual rent up to $6.9 million based on the new operator's revenue.

[Bob Stephenson, CFO at Omega Healthcare Investors]

In the second quarter, we received rental income of $2.8 million from the new operator, which consisted of $1.3 million of base minimum rent and $1.5 million of incremental rent. Turning to LaVie, they paid an additional $1.5 million in the second quarter, as their rent payment increased from $1.5 million per month to $3 million per month, starting in June. And lastly, Maplewood paid $11.8 million in rent in the second quarter versus $11.3 million in the first quarter. In July, Maplewood paid $4 million in rent. Our balance sheet continues to remain strong.

[Bob Stephenson, CFO at Omega Healthcare Investors]

On April 1, we repaid our maturing $400 million senior unsecured bond, using $360 million of balance sheet cash, April 1 rent collections, and borrowed the balance on the credit facility. In the second quarter, we completed $221 million in new investments, excluding CapEx, and funded the investments through the issuance of 7.6 million shares of common stock, or $245 million in equity proceeds under our ATM program. We ended the quarter with over $35 million in cash on the balance sheet and over $1.4 billion in credit facility borrowing capacity. At June 30, 99% of our $4.7 billion in debt was at fixed rates.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our net funded debt to annualized adjusted EBITDA was 4.76x, down from 5.0x in the first quarter, and our fixed charge coverage ratio was 4.3x. Turning to guidance, as Taylor mentioned, we increased our full year adjusted FFO guidance to a range between $2.78-$2.84 per share. A few of the key assumptions are: we're assuming no change in our revenue related to operators on accrual basis of revenue recognition. We're assuming LaVie continues to pay at the existing rate of $3 million per month, and Maplewood's ability to pay contractual rent continues to improve. We're assuming the new operator of the Guardian transition facilities will continue to pay rent of $2.8 million per quarter, consistent with the second quarter.

[Bob Stephenson, CFO at Omega Healthcare Investors]

We're assuming $77 million in asset sales in the second half of the year related to facilities classified as assets held for sale at the end of the second quarter, for which we recorded $1.4 million in revenue in the second quarter. We've included the annual impact of the 2024 investments and assumed debt completed through July 31, as outlined in the press release. We project our quarterly G&A expense to continue to run between $11.5 million-$13.5 million per quarter. We assume no material changes in market interest rates as they relate to either interest earned on our balance sheet cash or interest expense charged on credit facility borrowings. Additionally, our $245 million in ATM proceeds in the second quarter were raised through equity, predominantly issued in June.

[Bob Stephenson, CFO at Omega Healthcare Investors]

As such, the 7.6 million shares issued only had a weighted average diluted impact of 2.3 million shares in the second quarter. Had all the shares been included within the weighted average, adjusted FFO would have been diluted by approximately $0.01. Our weighted-average shares for the third quarter will include the full impact of the 7.6 million shares, plus any additional shares issued as we continue to fund new investments accretively with equity, while maintaining leverage under 5x. As a reminder, for every 4 million shares issued, our quarterly adjusted FFO is negatively impacted by approximately $0.01 per share until the cash is put back to work in new investments.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Our 2024 adjusted FFO guidance does not include any additional investments or asset sales, as well as any additional capital transactions other than what has already been mentioned. I will now turn the call over to Dan.

[Dan Booth, COO at Omega Healthcare Investors]

Thanks, Bob, and good morning, everyone. As of June 30, 2024, Omega had an operating asset portfolio of 900 facilities with approximately 86,000 operating beds. These facilities were spread across 77 third-party operators and located within 42 states in the United Kingdom. Trailing twelve-month operator EBITDAR coverage for our core portfolio as of March 31, 2024, increased to 1.42x, versus 1.33x for the trailing twelve-month period ended December 31, 2023. Occupancy for our overall core portfolio has continued to recover from a low of 74.6% in January of 2022 to 80.8% as of mid-July 2024, based upon preliminary reporting from our operators. Turning to portfolio matters.

[Dan Booth, COO at Omega Healthcare Investors]

LaVie, as previously announced, LaVie filed for Chapter 11 bankruptcy protection on June 2, 2024 in the Northern District of Georgia. Omega believes this filing was a necessary and important step in creating an entity that is operationally solvent and sustainable, with enhanced liquidity and a strengthened balance sheet. We continue to believe that there is meaningful value in our portfolio of current LaVie assets. Omega has been working with LaVie for over a year to assist it in reducing its continued exposure to underperforming assets, which in turn has alleviated some of the financial burdens on the current LaVie portfolio. We believe the current cash flow generated by our remaining LaVie portfolio is sustainable and will support long-term annualized rent of approximately $36 million, while also retaining sufficient cash within the business to provide for strong clinical care.

[Dan Booth, COO at Omega Healthcare Investors]

LaVie paid approximately $3 million in rent in the months of June, July, and August of 2024. Although the bankruptcy proceedings are still in process, Omega anticipates that the final resolution will be concluded prior to year-end of 2024. In addition to the aforementioned restructurings, Omega is working with several other relatively small operators on various restructurings. Turning to new investments. During the second quarter of 2024, Omega completed a total of $254 million in new investments, inclusive of $33 million in CapEx investments.

[Dan Booth, COO at Omega Healthcare Investors]

The new investments have a weighted average cash yield of 10.4%, with annual escalators ranging from 2%-2.5%, and include the following: A $62.7 million sale-leaseback transaction, whereby Omega acquired 32 care homes in the U.K. and leased these facilities back to a new operator. A $31 million sale-leaseback transaction, whereby Omega acquired one facility in Michigan and leased it back to an existing operator. A $21 million sale-leaseback transaction, where Omega acquired one facility in Louisiana and leased it back to a new operator, and four separate loans to existing operators, totaling $106 million. Subsequent to the second quarter of 2024, Omega closed on $373 million in new investments, excluding CapEx.

[Dan Booth, COO at Omega Healthcare Investors]

These investments include the aforementioned buyout of our 51% JV partner in 63 care homes in the U.K. The facilities are leased to two established U.K. operators, with current annual rent of $43.6 million. Omega's total investment is now $436 million, which results in a gross return of 10%. Year to date, through July, Omega has closed on $702 million in new investments, inclusive of CapEx investments through the second quarter. I will now turn the call over to Megan.

[Megan Krull, Senior Vice President of Operations at Omega Healthcare Investors]

Thanks, Dan, and good morning, everyone. As discussed last quarter, the staffing mandate was finalized in April, despite the inability of most facilities to meet the requirements and with limited visibility into the structural implication from a labor perspective, in terms of how to create access to the level of staffing required of the mandate. While it is unlikely that any of the levers, legislative or otherwise, to adjust or overturn the rule, would be successful prior to the election, it is important to note that, as previously expected, certain industry associations, along with several operators, have filed a lawsuit to overturn the mandate.

[Megan Krull, Senior Vice President of Operations at Omega Healthcare Investors]

Although it will take some time for the outcome of the lawsuit to be determined, both the Supreme Court's recent move to overturn the Chevron doctrine, which gave deference to regulatory bodies in interpreting laws, and the fact that the attorney who successfully argued for Chevron to be overturned is the same as being used in the case against the mandate, certainly appear to weigh in favor of the ultimate success of the lawsuit against the staffing mandate. The fundamentals of the business continue to improve. While not at pre-pandemic levels, occupancy has stabilized, and the recovery from a coverage perspective is indicative of the fact that many states have and continue to step up in meaningful ways to provide the support necessary in recovery efforts. We hope they do the same in the face of any and all regulatory pressures going forward.

[Megan Krull, Senior Vice President of Operations at Omega Healthcare Investors]

CMS, as well, issued its final 2025 payment rule this week, resulting in a net increase of 4.2% or approximately $1.4 billion, which is slightly better than the 4.1% provided for in the proposed rule. This included a 3% market basket increase, plus a 1.7% market basket forecast error adjustment, offset by a 0.5% productivity adjustment. So while there continues to be, and likely always will be, some level of pressure on the industry from a regulatory perspective, hopefully cooler heads will always prevail and the ultimate scrutiny will be well balanced and achieve a level of reasonableness indicative of an understanding of the industry as a whole. I will now open the call up for questions.

[Operator]

Thank you. We will now be conducting the question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. We ask that you please limit your questions to one question and one follow-up to allow time for as many questions as possible. Our first question is coming from the line of Jonathan Hughes with Raymond James. Please proceed.

[Jonathan Hughes, Analyst at Raymond James]

Hi, good morning. Thank you for the prepared remarks and commentary. I was hoping you could share some details of, of what the investment pipeline looks like today in terms of size, yields, skilled nursing versus assisted living, and then, you know, acquisitions versus loans.

[Dan Booth, COO at Omega Healthcare Investors]

Sure. So, as we indicated last quarter, and remains today, our pipeline is very active. We're seeing a lot of deals, both here in the States and over in the U.K. You know, our average yield is a little up north of 10%, which is consistent with what we're seeing in the market. You know, if you compare that, you know what? As we indicated on the call, we did just over $700 million of deals through July of 2024. If you compare that to last year, we had done just over $300 million of deals through the same time period, so we've more than doubled that. And once again, that, that's just a result of a very active pipeline.

[Jonathan Hughes, Analyst at Raymond James]

Okay. Are you seeing, you know, any more private capital competitors come back to the space, or are they still largely on the sidelines, you know, due to the challenging bank lending environment?

[Dan Booth, COO at Omega Healthcare Investors]

So we haven't seen them. So if they've come back, we're, we're not seeing them in any material. So.

[Jonathan Hughes, Analyst at Raymond James]

Okay, and then just one more from me for Bob. The equity raise via the ATM in the quarter, I think it was the most since second quarter of last year, and obviously is an accretive source of capital to fund acquisitions and leverages now, you know, sub five times. There's plenty of capacity on the revolver. Hoping you could just talk more about how you think of funding investment activity going forward and early thoughts on addressing the 2025 debt maturities. Thanks.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Absolutely. I think your first statement hit it dead. We could do all acquisitions accretively using equity right now, and we wanna continue to do that to maintain our leverage less than 5x. So, you know, looking forward, we'll continue to do that.

[Jonathan Hughes, Analyst at Raymond James]

Then just thoughts on the maturities for next year.

[Bob Stephenson, CFO at Omega Healthcare Investors]

Yeah. You know, we have $400 million coming up on January fifteenth, and we'll get in front of that, similar to the way we got in front of our $400 million that we just paid off in April. So in the fourth quarter, you know, we'll sit down and look at the market to see whether it's bond for bond, but more likely it would be equity.

[Jonathan Hughes, Analyst at Raymond James]

All right. Thanks for the time.

[Operator]

Thank you. Our next question is coming from the line of Michael Griffin with Citi. Please proceed with your question.

[Michael Griffin, Analyst at Citi]

Great, thanks. I'm wondering if you could give some more color, just on the buyout of your partner's stake in the Cindat joint venture. You know, can you give us a sense, were there any capital or liquidity constraints that your partner had, might have been wanting to, you know, for them to sell their, their stake, kind of the driving force behind that? And then you, you quoted the interest rate on it. If you were to refi it, I, I guess, when the debt comes due next year, how much benefit from the accretion do you think you'd get?

[Taylor Pickett, CEO at Omega Healthcare Investors]

Yeah, I think, Michael, you're coming out. It was a little bit difficult to hear you, but I think I got your question. The Cindat-- the relationship within the JV, when we first set it up, we had buy/sell provisions, and we just felt like the timing was good from a market perspective to trigger that. The 51% partner had the opportunity to match the bid and take us out, and they elected not to do so. We thought we got it at a really attractive price when you look at, ten percent yields ultimately on that asset. Unfortunately, it came with a piece of paper that's not all that attractive. Our, our cost of capital, debt capital, would be about 6%. So you look at the differential there, it's 4.38% on $243 million. I mean, that's essentially the pickup with the refi.

[Michael Griffin, Analyst at Citi]

Great, appreciate the color there, Taylor. And then just on the Guardian portfolio, just wanted to get a sense, is there something that the new operator is doing differently that, that Guardian wasn't? You know, I thought Pennsylvania was a relatively tough state to operate in, but any color you have there would be helpful.

[Dan Booth, COO at Omega Healthcare Investors]

I'm not sure I heard all that question. The facilities in Pennsylvania were struggling, I can tell you that. We moved in there in the second quarter. You know, we set up kind of a unique rent structure that had basically a revenue kicker embedded in it. If the operator performed well, which they did, the kicker, if you will, kicked in in the second quarter. We were able to receive the higher rent, and we expect that to go forward through the remainder of the year.

[Michael Griffin, Analyst at Citi]

Great. That's it for me. Thanks for the time.

[Operator]

Thank you. Our next question is coming from Jamie Feldman with Wells Fargo. Please proceed with your question.

[Jamie Feldman, Analyst at Wells Fargo]

Great. Thanks for taking the question. I guess just starting, you have a decent number of mortgage and other real estate-backed investments maturing in 2024 and 2025. Can you talk about the plans for those and the opportunity to refine, you know, to put that capital to work at a similar rate, or how you think that plays out for earnings?

[Dan Booth, COO at Omega Healthcare Investors]

So, you know, we've got... They're kind of onesie mortgages that are coming due over the course of the next, call it, 12 months. No one in particular is that material. We expect some of those to pay off, and we expect some of those to be extended. I don't think we're gonna see a lot of dollars rolling back, but yeah, they were short-term mortgages ones for the most part, a little mezz sprinkled in there.

[Jamie Feldman, Analyst at Wells Fargo]

Okay. And do you think, like, I guess it's obviously in 2024, but for 2025, you think it's neutral to earnings? Or you can?

[Dan Booth, COO at Omega Healthcare Investors]

Yeah, it shouldn't have any material impact at all on earnings.

[Jamie Feldman, Analyst at Wells Fargo]

Okay. And then it looks like the investment environment's been pretty favorable this year. Can you talk about what you're seeing, more in, particularly in the U.K., where it seems like you've had more opportunities recently? How much do you think you might put to work there, and, and what the opportunity set looks like going forward?

[Dan Booth, COO at Omega Healthcare Investors]

You know, both the States and the U.K. is quite active right now. I think what we have going for us in the U.K. is that there's not as many capital players over there just yet. I mean, they had a quicker recovery overall from COVID. So we got in there pretty quick, and we haven't seen a lot of capital players come into that market yet, so we're able to pick and choose, and we're being opportunistic at this point in the U.K., looking at really kind of all facets of care homes.

[Jamie Feldman, Analyst at Wells Fargo]

Okay. How would you frame, like, the magnitude of the investment opportunity?

[Taylor Pickett, CEO at Omega Healthcare Investors]

I would think about the pipeline. The pipeline that created the opportunities that we've seen in the first seven months of this year hasn't changed. So you never can predict when stuff's gonna come through, but it's a similar pipeline in terms of the opportunity set that we're seeing.

[Jamie Feldman, Analyst at Wells Fargo]

Okay. And then finally, can you just give an update on the Second Avenue Maplewood project? What your thoughts are on lease-up, how you think that develops into the back half of 2024 and early 2025?

[Taylor Pickett, CEO at Omega Healthcare Investors]

Yeah. So, Second Avenue continues to ramp up in a market where there's a lot of new product. I mean, we're the first in, but there's three buildings that followed us in Manhattan, and we're doing well, 67% occupied, and we'll continue to trend up. But remember also, the building has matured, so you have residents that pass away and are being backfilled with new residents. So it's. You know, I'm not sure. It's tough to predict when we get to 90%, but there's certainly a pathway, and they continue to do well.

[Jamie Feldman, Analyst at Wells Fargo]

Okay. All right. Thank you for your thoughts.

[Operator]

Thank you. The next question is coming from the line of Vikram Malhotra with Mizuho. Please proceed with your question.

[Vikram Malhotra, Analyst at Mizuho]

Good morning. Thanks for taking the question. I just wondered if you could expand on the Maplewood point, and maybe just also give us an update just on D.C. But just in New York, it seems like you said there's a lot of competition, maybe some discounting, lease-up's a bit slower. Any statistics you can share, like I think you did at Mary, to give us some statistics on move-in, move-out, sort of occupancy? Just what are you anticipating for the lease-up to sort of a run rate where you can get a full rent?

[Taylor Pickett, CEO at Omega Healthcare Investors]

Yeah. Timing is impossible to predict, but, I will say this: There has been, as you mentioned, there's been some discounting of product in Manhattan. Fortunately, there's not so much price sensitivity in Manhattan. If somebody is, you know, property is desirable, you can pretty much hold prices. So you think about, Second Avenue, which has 120 residents, so it's a vibrant community. Already, it shows very well. It, the care is exceptional, and that's why we're able to get RevPAR of $22,000 a month. So, I think we have everything headed in the right direction. But to answer the question, when 67% get to 90%, not this year, probably. Maybe you're looking at 2025.

[Taylor Pickett, CEO at Omega Healthcare Investors]

And then just to close the loop on Maplewood, there were really three key things for us, with that team. One is transitioning operations out of the Greg Smith estate. One was stabilizing that operating balance sheet, and the last is the ramp-up of Second Avenue. The balance sheet's been stabilized, the transition of operations is in process, and the ramp-up's on its way. The rest of that core portfolio, the other 16 facilities, do incredibly well. So you have this solid base that fully supports the current rent, and we feel really good about the outlook. It's just timing is impossible to predict.

[Vikram Malhotra, Analyst at Mizuho]

Okay, thanks. And then just, Bob, a follow-up on the. You mentioned the share count impact into 3Q, but just putting everything together, just on FAD, am I correct in the ballparks that your $0.68 in the quarter sort of goes to $0.70, $0.71 in the back half?

[Bob Stephenson, CFO at Omega Healthcare Investors]

That's the math that would fit the range. Yes.

[Vikram Malhotra, Analyst at Mizuho]

Got it. Okay. And then just, sorry, just to clarify, you said you mentioned the acquisitions that closed in the quarter. That also includes that that's basically the loans as well as the deals that you've done in terms of the impact going forward into 3Q and 4Q, correct? In terms of the deals that you announced in the 3Q, as you bake that into the run rate. I just wanted to clarify the timing of those deals just so that we can model it out into the third and fourth quarter.

[Bob Stephenson, CFO at Omega Healthcare Investors]

We've baked those in. I said all acquisitions completed through July 30th were baked into the guidance.

[Vikram Malhotra, Analyst at Mizuho]

Got it. Okay. Thanks so much, and congrats on a strong quarter.

[Operator]

Thank you. Our next question is coming from the line of Juan Sanabria with BMO Capital Markets. Please proceed with your question.

[Robin Handel, Analyst at BMO Capital Markets]

This is Robin sitting in for Juan. Just curious on Maplewood, why did Washington, D.C., development budget increase by $50 million?

[Taylor Pickett, CEO at Omega Healthcare Investors]

Oh, yeah, D.C., that really relates to what we've seen in construction costs over the last three years. Not just in this industry, but across almost all construction industries. This is a 25% increase, and it just reflects the fact that, that when we close this out, that's what it's gonna end up costing.

[Robin Handel, Analyst at BMO Capital Markets]

Okay. And on the sub one coverage, what's the expected trend into 2025, and how long, how low can this exposure reasonably get to?

[Taylor Pickett, CEO at Omega Healthcare Investors]

I think there's a couple of things that are interesting there. We have a number of operators that the EBITDA coverage is above 1. And so there's a handful of those operators that I think just naturally work their way out of the bucket, including one larger, the largest operator. And then there's a handful of smaller operators that are-- we're currently working through some restructuring activity, and I think they'll come out of the bucket. And we probably settle at less than 2% going into 2025. That's, that would be the goal. And that's normal. If you look at our history for 20 years, we've always had 2%-4% in that bucket.

[Robin Handel, Analyst at BMO Capital Markets]

Thank you.

[Operator]

Thank you. Our next question is coming from the line of Justin Haasbeek with RBC Capital Markets. Please proceed with your question.

[Justin Haasbeek, Analyst at RBC Capital Markets]

Yeah, thanks. You mentioned that the new operator for the Guardian assets can continue to pay $2.8 million in total quarterly rent for the remainder of the year. How should we think about this portfolio going forward into next year? And just how volatile could this rent be going forward?

[Dan Booth, COO at Omega Healthcare Investors]

You know, it once again, it's revenue. There's revenue-based kickers, so we could move around, but right now, based upon second quarter results, we think that that's sustainable, and that's what we're going to see going forward.

[Operator]

Thank you. We'll move on to our next question, which is coming from the line of Alex Fagan with Baird. Please proceed with your question.

[Alex Fagan, Analyst at Baird]

Hello, good morning. Thank you for taking my question. First, on the Cindat JV, which you guys bought out, how are the two operators in that portfolio performing? Can you share any metrics about EBITDA coverage or anything else?

[Taylor Pickett, CEO at Omega Healthcare Investors]

Their coverage is consistent with what we see in our overall portfolio, so, nothing unusual there in terms of underwriting. Really kind of down the middle type portfolios for us.

[Alex Fagan, Analyst at Baird]

All right. Would you be able to provide an update on the $109 million of other real estate loans that were due in 2024, that were extended from March 29th to June 28th? Were those paid out or any update there?

[Taylor Pickett, CEO at Omega Healthcare Investors]

Oh, yeah. I mean, it's a fully collateralized loan. There's plenty of liquidity, in a market that's a little tough to borrow, and so we were very comfortable extending that loan out.

[Alex Fagan, Analyst at Baird]

But the loan was extended to June 28, 2024. Has that been paid back or extended again?

[Taylor Pickett, CEO at Omega Healthcare Investors]

You know what? We're all looking at each other, trying to figure out what loan it is. Can I just have Bob circle back with you on that? Because I don't want to mistake anything.

[Alex Fagan, Analyst at Baird]

Yes, no worries. That's it for me. Thank you, guys.

[Operator]

Thank you. The next question is coming from Joshua Dennerlein with Bank of America. Please proceed with your question.

[Farrell Granath, Analyst at Bank of America]

Hi, this is Farrell Granath on behalf of Josh. I was wondering if you could also go back to the Guardian assets or the new tenants. Just in understanding the mechanics, and with the rent, and I understand with the revenue kicker, is that evaluated throughout the quarter? Is it, is there a certain timing adjustment that we should be thinking that if they're hitting certain revenue goals, that that's being evaluated, that that would be increased?

[Bob Stephenson, CFO at Omega Healthcare Investors]

It was evaluated in the second quarter. As I indicated, they did meet the criterion of having the kicker kick in at, to the extent that we reported it. We do believe it's sustainable. It will continue to go forward quarter after quarter throughout the year. There's no more magic to it.

[Farrell Granath, Analyst at Bank of America]

Or at least does it get reevaluated from going forward for that excess amount that they could continue to go up?

[Dan Booth, COO at Omega Healthcare Investors]

Once again, I think that the revenue that they recorded in the second quarter is sustainable, so I don't think it's gonna go either up nor down. It's gonna pretty much remain flat.

[Farrell Granath, Analyst at Bank of America]

Okay, thank you so much. And also, in terms of the uptick that we saw in the occupancy and coverage data of your operators, was there any specific at least facility type or operator that's performing better than others or a standout?

[Megan Krull, Senior Vice President of Operations at Omega Healthcare Investors]

You mean in terms of like SNF versus ALF or?

[Farrell Granath, Analyst at Bank of America]

Yes.

[Megan Krull, Senior Vice President of Operations at Omega Healthcare Investors]

I mean, I think, you know, we've, we've historically, since COVID, seen the ALF product come back a little bit quicker, but I think generally speaking, we're seeing census increase at all of them. The SNF is now sort of catching up.

[Farrell Granath, Analyst at Bank of America]

Okay, thank you so much.

[Operator]

Thank you. There are no further questions at this time. I would like to turn the floor back over to Taylor Pickett for closing comments.

[Taylor Pickett, CEO at Omega Healthcare Investors]

Thanks, everyone, for joining our call today. Please feel free to follow up with the team.

[Operator]

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. We thank you for your participation.

Participants

Executives

• Bob Stephenson, CFO
• Dan Booth, COO
• Megan Krull, Senior Vice President of Operations
• Michele Reber, Managing Director of Operations
• Taylor Pickett, CEO

Analysts

• Alex Fagan, Analyst at Baird
• Farrell Granath, Analyst at Bank of America
• Jamie Feldman, Analyst at Wells Fargo
• Jonathan Hughes, Analyst at Raymond James
• Justin Haasbeek, Analyst at RBC Capital Markets
• Michael Griffin, Analyst at Citi
• Robin Handel, Analyst at BMO Capital Markets
• Vikram Malhotra, Analyst at Mizuho